Explorer Series 3: NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate

Dr. Woodhouse became Chief Executive Officer and a member of NGM’s board of directors in September 2018. He previously served as NGM’s Chief Financial Officer, joining the company in March 2015. From 2002 to 2015, he was an investment banker at Goldman Sachs & Co. LLC, most recently as a Managing Director in the healthcare investment banking group and co-head of biotechnology investment banking. Earlier in his career, Dr. Woodhouse worked at Dynavax Technologies and also as a research assistant at Amgen, Inc. Dr. Woodhouse received a B.A. in pharmacology from the University of California, Santa Barbara, an M.B.A. from the Tuck School of Business at Dartmouth and a Ph.D. in molecular pharmacology from Stanford University School of Medicine.

Dr. Marco Colonna received his medical degree and specialization in internal medicine at Parma University (Parma, Italy) and completed his postdoctoral training at Harvard Medical School (Cambridge, Massachusetts, USA). He became a scientific member of the Basel Institute for Immunology (Basel, Switzerland). Since 2001 he has been a Professor of Pathology & Immunology at Washington University School of Medicine in St. Louis, MO, USA. Since 2019 Dr. Colonna is a member of the National Academy of Science. Dr. Colonna’s research focuses on immunoreceptors. In this field his accomplishments encompass identification and characterization of the Killer cell Ig-like receptors and HLA-C polymorphisms as their inhibitory ligands, as well as the discovery of the LILR and TREM inhibitory and activating receptor families. Through analysis of the cellular distribution of these receptors, he identified plasmacytoid dendritic cells as source of IFN-/ in anti-viral responses and innate lymphoid cells that produce IL-22 in mucosae. His current areas of research include: 1) Innate lymphoid cells in mucosal immunity. 2) Plasmacytoid dendritic cells in host defense and autoimmunity.3) TREM2 and innate immunoreceptors in Alzheimer’s disease and cancer.

Dr. Stone joined NGM Bio in 2016. He is responsible for NGM Translational Research efforts in Immune-Oncology and serves as Research Lead for NGM707. Previously, Dr. Stone directed drug discovery efforts for ILT2 and ILT4 therapeutics as well as the discovery and development of additional IO candidates. His lab focuses on myeloid cell biology in the context of tumor development. Prior to NGM, Dr. Stone was Assistant Professor in Microbiology and Immunology at the University of Miami Sylvester Comprehensive Cancer Center and Miami Center for AIDS Research. Dr. Stone obtained his PhD in Biochemistry from the University of British Columbia and completed additional postdoctoral training at Stanford University and the University of California, San Diego.

Dr. Kaplan joined NGM in 2008. He heads NGM’s Translational Immune-Oncology group and serves as leader of the NGM707 (anti-ILT2/ILT4) development team. He has directed drug discovery efforts across numerous therapeutic areas, including metabolic diseases and oncology. For the past seven years, his team has worked to understand the suppressive mechanisms at play in the tumor microenvironment, and how these mechanisms restrict anti-tumor immune responses in many cancers. They have elucidated “myeloid checkpoints” that mediate immune suppression in tumors, and they have identified therapeutic targets for relieving these checkpoints. Dr. Kaplan obtained his Ph.D. from Duke University, where he was a Howard Hughes Medical Institute predoctoral scholar, and completed postdoctoral training at Stanford University, where he was an American Cancer Society fellow.

Prior to joining NGM, Ms. Nolan Mangini served as President and Chief Financial Officer (CFO) of Castlight Health, a publicly traded San Francisco-based healthcare technology company. She joined Castlight in 2012 and assumed roles of increasing responsibility, ultimately being appointed CFO in 2016 followed by her additional appointment as President in 2019. At Castlight, Ms. Nolan Mangini was responsible for a wide range of functions including strategic and corporate planning, finance, investor relations, people, legal, real estate, customer support and business operations. Prior to joining Castlight, Ms. Nolan Mangini worked as a management consultant at Bain & Company, specializing in the health care and private equity practices. She began her career at the Henry J. Kaiser Family Foundation as a financial associate responsible for managing the allocation of the foundation’s endowment. Ms. Nolan Mangini currently serves on the Board of Directors of Artemis Health. Ms. Nolan Mangini has a Master of Business Administration from the Graduate School of Business at Stanford University, a Master of Public Administration from the Kennedy School of Government at Harvard University and a Bachelor of Science in Economics from the Wharton School at the University of Pennsylvania.